| Name | Title | Contact Details | 
|---|---|---|
| Brendan O'Malley | Senior Vice President, General Counsel | Profile | 
| Kate Imhoff | Senior Director of Regulatory Affairs | Profile | 
| Carl Denny | Vice President and Head of Regulatory Affairs | Profile | 
| Brendan O`Malley | Senior Vice President and General Counsel | Profile | 
| Neena Patil | General Counsel | Profile | 
NDD Medical Technologies is a Andover, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Armata is a clinical-stage biotechnology company focused on the development of precisely targeted bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology.
Nuvalent is creating precisely targeted therapies for patients with cancer designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in structure-based design, Nuvalent develops innovative small molecules with exquisite target selectivity to overcome resistance, minimize adverse events, and drive more durable responses. Nuvalent is advancing a robust pipeline with parallel lead programs in ROS1-positive and ALK-positive NSCLC, along with multiple discovery-stage research programs.
MBX Biosciences is a preclinical-stage biotechnology company using validated molecular targets to create medicines for rare endocrine diseases where current therapies are inadequate.
Capital Royalty L.P. is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.